Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

The Invesco Pharmaceuticals ETF (PJP), a $239.95 million smart beta fund, provides concentrated exposure to U.S. pharmaceutical companies, tracking an index based on fundamental criteria. With a 0.56% expense ratio, the fund has delivered modest returns of 0.8% year-to-date and 2.82% over the past year (as of 07/10/2025). Its portfolio of 31 holdings and a three-year standard deviation of 15.71% indicate a higher-risk, more concentrated option compared to larger, lower-cost alternatives like the iShares U.S. Pharmaceuticals ETF (IHE) and VanEck Pharmaceutical ETF (PPH).

Analysis

The Invesco Pharmaceuticals ETF (PJP) is a smart beta fund offering concentrated exposure to the U.S. pharmaceutical sector, distinguished by its use of the Dynamic Pharmaceutical Intellidex Index which selects stocks based on fundamental growth, valuation, and risk factors. With $239.95 million in assets, PJP is an average-sized fund in its category, but its 0.56% expense ratio is notably higher than those of larger peers. The fund's portfolio structure reflects a high-conviction approach, with only 31 holdings and the top 10 constituents accounting for 46.64% of total assets. Despite its strategy aimed at capital appreciation, performance has been modest, with a year-to-date gain of 0.8% and a one-year return of 2.82%. Critically, the fund is characterized as a high-risk option, supported by a three-year standard deviation of 15.71%, which is significant given its low market beta of 0.47, indicating substantial idiosyncratic risk. In comparison, alternatives like the iShares U.S. Pharmaceuticals ETF (IHE) and the VanEck Pharmaceutical ETF (PPH) offer lower expense ratios of 0.39% and 0.36% respectively, alongside much larger asset bases.

Key Decisions for Investors

• Investors should weigh PJP's high 0.56% expense ratio and 15.71% standard deviation against its modest recent performance, as these factors present a challenging risk-return profile.
• Given its concentrated nature with only 31 holdings, this ETF is more suitable for investors with a specific bullish thesis on its proprietary index methodology rather than for those seeking broad, low-cost sector exposure.
• It is prudent to compare PJP directly against lower-cost and larger alternatives like IHE and PPH, which may offer a more efficient vehicle for gaining exposure to the U.S. pharmaceuticals market.
• Monitor the fund's performance closely to determine if its smart beta strategy can generate alpha sufficient to justify its higher fees and elevated specific risk profile over time.